Stay updated with breaking news from Kamada Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDA – Free Report) in a research note published on Thursday morning. The brokerage issued a buy rating on the biotechnology company’s stock. Separately, HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Kamada in a report on Thursday, May 9th. View […]
StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA – Free Report) in a report published on Thursday morning. The firm issued a buy rating on the biotechnology company’s stock. Separately, HC Wainwright reissued a buy rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, May 9th. Check Out […]
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and
Dr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development